Cases & Points Blog

Confusion, Conjecture and Clarification: The New WCMSA Reference Guide

With the issuance of updated Workers’ Compensation Medicare Set-Aside Reference Guide version 2.9 (Guide), there has some speculation and even confusion as to what is really new and what is an elaboration of old policies and procedures.  Examples listed for off-label drug usage to new bullets added regarding the submission process, all of which begs the question, what is CMS really saying and how is it being interpreted?

One area of confusion surrounds Section 4.2 of the Guide.  This Section now includes an additional bullet point which states as follows:

CMS’ voluntary, yet recommended, WCMSA amount review process is the only process that offers both Medicare beneficiaries and Workers’ Compensation entities finality, with respect to obligations for medical care required after a settlement, judgment, award, or other payment occurs. When CMS reviews and approves a proposed WCMSA amount, CMS stands behind that amount. Without CMS’ approval, Medicare may deny related medical claims, or pursue recovery for related medical claims that Medicare paid up to the full amount of the settlement, judgment, award, or other payment.

There has been some speculation that based upon this new provision, that the only way to protect Medicare’s interest is through the submission process and that CMS submission of a WCMSA is essentially mandatory.  This is simply not the case.  CMS submission is still a very much a voluntary process and this is noted in various parts of the Guide.  In fact, the first sentence of Section 4.2 states that “[s]ubmitting a WCMSA proposed amount is never required.”  What is required is ensuring that Medicare’s interest is “always” protected.

When determining the vehicle to best protect Medicare’s interest there are both submission and non-submission options. The impact of over-inflated WCMSA determinations and potential delays that can thwart settlement are some considerations to address when making this decision.  When utilizing a non-submission option it is important to also assess whether the entity performing this allocation will also “stands behind” it as Medicare purports to do.  In addition, questioning the type of assurances being offered and the duration of the same is also of critical importance when deciding what is best for your case.

Section 8.1 of the Guide entitled “Review Thresholds” now includes examples of protecting Medicare’s interest when submission review thresholds are not met.  Specifically, Section 8.1 provides in pertinent part as follows:

Example 1: A recent retiree aged 67 and eligible for Medicare benefits under Parts A, B, and D files a WC claim against their former employer for the back injury sustained shortly before retirement that requires future medical care. The claim is offered settlement for a total of $17,000.00. However, this retiree will require the use of an anti-inflammatory drug for the balance of their life. The settling parties must consider CMS’ future interests even though the case would not be eligible for review. Failure to do so could leave settling parties subject to future recoveries for payments related to the injury up to the total value of the settlement ($17,000.00).

Example 2: A 47-year-old steelworker breaks their ankle in such a manner that leaves the individual permanently disabled. As a result, the worker should become eligible for Medicare benefits in the next 30 months based upon eligibility for Social Security Disability benefits. The steelworker is offered a total settlement of $225,000.00, inclusive of future care. Again, there is a likely need for no less than pain management for this future beneficiary. The case would be ineligible for review under the non-CMS-beneficiary standard requiring a case total settlement to be greater than $250,000.00 for review. Not establishing some plan for future care places settling parties at risk for recovery from care related to the WC injury up to the full value of the settlement.

CMS has always maintained that Medicare’s interest must be protected even in cases that do not meet the workload review thresholds and failure to meet these thresholds do not provide the parties with any type of “safe harbor.”  These examples expand upon this requirement by illustrating the need for some type of future care plan when there is a claim involving a Medicare beneficiary or someone within thirty (30) months of becoming a beneficiary.  Of note, this Section also does not limit recovery efforts to just one party to the settlement, but, instead, all “settling parties” are “at risk.”

In the event there is not court decision on the merits limiting future medical liability or a treating physician certification evidencing that no future treatment is required, utilizing a Set-Aside allocation in these cases and referencing it in the settlement can help manage or eliminate the risk of future exposure.

CMS has also removed references to policy Memoranda in the new Guide.  Specifically, in Section 1.0, CMS notes that that information in the new Guide was gathered from Memoranda issued by CMS, information on the CMS Website, information provided by the WCRC and WCMSA Operating Rules.  CMS states that the intent of the Guide is to “consolidate and supplant all historical memoranda in a single point of reference.”  CMS also states that reference to these prior documents should be discontinued.

One Memoranda that was specifically deleted from Section 4.1.1 of the Guide entitled Commutation and Compromise is the July 2001 WC RO Memorandum commonly referred to as the Patel Memo.  Although containing the same verbiage as Guide 2.8, Guide 2.9 does not direct parties to the Patel Memo for further explanation on how to address compromise vs. commutation situations when considering the need for a WCMSA.  Despite this fact, there is no specific indication that this deletion will have any specific impact on this determination.  However, we will continue to monitor this should further clarification be provided.

Section 16.0 of the Guide entitled Re-Review also provided additional clarification on what constitutes a mathematical error and what should be submitted in certain re-review disputes.  Specifically, this Section provides as follows:

  • Disagreement surrounding the inclusion or exclusion of specific treatments or medications does not meet the definition of a mathematical error.
  • Re-Review requests based upon failure to properly review already submitted record must include only the specific documentation referenced as a basis for the request.

CMS also noted that in addition to not being able to supplement a re-review, no development requests will be made by CMS requesting additional information.  What is clear from this provision is that parties must ensure that all documentation necessary to support a Re-Review/Amended Review is submitted in the first instance to avoid CMS denials.  This requires a critical review of medical records, court orders, and other documentation to support this change.  Further, this needs to presented to CMS in a clear and concise fashion.

NuQuest’s prior blog addressed changes to Section 9.4.5 and 9.3 regarding Spinal Cord Stimulator pricing which has been consistent with CMS approvals. In addition, our prior blog discussed the impact and continued inclusion of more and more off-label prescription medications in the WCMSA allocation.  As noted in the new example issued by CMS in Section 9.4.6.2 of the Guide involving Lyrica, CMS has clearly broadened what it will rely on to support the inclusion of an off-label medication in the WCMSA.  This shift has caused the cost of some WCMSAs to increase significantly.  Based upon the foregoing, parties need to critically review the use of off-label medications prior to submitting a WCMSA to CMS for review.

Section 18.0 of the Guide entitled CMS Monitoring provides some insight into how CMS identifies claims that should not be paid based upon the existence of a WCMSA.  Specifically, this Section provides in pertinent part as follows:

Additionally, the contractor must ensure that Medicare makes no payments related to the WC injury until the WCMSA has been used up. This is accomplished by placing an electronic marker in CMS’ systems used to pay or deny claims. That marker is removed once the beneficiary can demonstrate the appropriate exhaustion of an amount equal to the WCMSA plus any accrued interest from the account. For those with structured settlements, the marker is removed in any period where the beneficiary exhausts their available funds; however, it is replaced once the anniversary fund deposit occurs until the entire value of the WCMSA is demonstrated as entirely exhausted.

The use of this marking system highlights the fact that CMS is monitoring the claim until the proper exhaustion of the WCMSA which could take place anytime in the future.  CMS does not limit the denial of payments to a one, two, four, or a ten year period.

Other noteworthy changes in the Guide include the following:

  • In Section 10.5.2 of the Guide, CMS noted that currently Indiana, Iowa, Missouri, New Hampshire, New Jersey and Wisconsin do not use fee schedule pricing. Virginia was deleted from this list.  Failure to use the proper pricing for the state will result in a different MSA allocation.
  • Section 17.3 Use of Account notes that if payments from the WCMSA are used for services that are not Medicare-covered allowable expenses for the WC injury or illness, Medicare will deny injury-related claims “until the WCMSA administer can demonstrate appropriate use equal to the full amount of the WCMSA.”
  • The Development Letter Sample now includes the contact and phone number of the Workers’ Compensation Review Contractor (WCRC) at (833)295-3773 instead of the CMS Regional Office.
  • As of January 5, 2019, CMS has converted to CDC life table for the total population: United States, 2015 when calculating life expectancy for the WCMSA.

NuQuest will continue to provide Medicare Compliance Updates as they become available.  Should you have any questions regarding the above, please do not hesitate to contact the NuQuest Legal Team.

 

CMS Issues a Revised WCMSA Reference Guide and Section 111 User Guide

The Centers for Medicare and Medicaid Services issued a revised WCMSA Reference Guide (Reference Guide), Version 2.9, which can be found here: WCMSA Reference Guide.  In addition to changes to development and alert templates; references to removal of certain memorandum from cms.gov; and reference to the updated CDC Life Table, the Reference Guide also includes updates to Spinal Cord Stimulators (SCS), and the inclusion of Lyrica, Trazodone and other off-label drugs in an MSA.

Section 1.1 of the Reference Guide state as follows:

  • To eliminate issues around Development Letter and Alert templates auto-populating with individual Regional Office (RO) reviewer names and direct phone numbers, these will now display the generic “Workers’ Compensation Review Contractor    (WCRC)” and the WCRC customer service number “(833) 295-3773” (Appendix 5).
  • Per CMS’ request, certain references to memoranda on cms.gov have been removed.
  • The CDC Life Table has been updated for 2015 (Section 10.3).
  • Updates have been provided for spinal cord stimulators and Lyrica (Sections 9.4.5 and 9.4.6.2).

With respect to SCS, Section 9.4.5 now includes the following language:

Routine replacement of the neurostimulator pulse generator includes the lead implantation up to the number of leads related to the associated code. Revision surgeries should only be used where a historical pattern of a need to relocate leads exists…

Surgery pricing may include physician, facility, and anesthesia fees. SCS pricing is based on identification of: 1.) Rechargeable vs. Non-rechargeable and 2.) Single vs. Multiple Arrays (leads). If unknown, CMS will default to non-rechargeable single array.

This pricing methodology outlined by CMS is consistent with recent CMS approval trends.

In addition, traditionally excluded from MSAs based upon off-label usage arguments, CMS has recently included Lyrica in certain allocations.  The new Reference Guide specifically addresses off-label usage arguments with respect to Lyrica as follows:

Example 1: Lyrica (Pregabalin) is cited in MicroMedEx for an off-label medication use related to neuropathic pain from spinal cord injury, and a number of scientific studies indicate that Pregabalin shows statistically significant positive results for the treatment of radicular pain (a type of neuropathic pain). Spinal cord neuropathy includes injuries directly to the spinal cord or its supporting structures causing nerve impingement that results in neuropathic pain. Lyrica is considered acceptable for pricing as a treatment for WCMSAs that include diagnoses related to radiculopathy because radiculopathy is a type of neuropathy related to peripheral nerve impingement caused by injury to the supporting structures of the spinal cord.

The language above utilized by CMS for the inclusion of Lyrica in the MSA may be an indication of things to come not only with respect to more and more allocations including this medication, but inclusion of additional off-label medications that were previously excluded from the MSA. A second example in the Reference Guide describes circumstances in which Trazodone will be included in MSAs.

In addition to the new WCMSA Reference Guide, CMS has also issued a new Section 111 NGHP User Guide (Guide).  The updated Guide includes the confirmation that the review threshold for reporting in 2019 will remain $750 for liability insurance settlements, judgments awards or other payments and $750 for no-fault and workers’ compensation claims where there is no ongoing responsibility for medicals (ORM) that was previously posted by CMS.  The Guide can be found here – Full Guide for further review and reference.

NuQuest will continue to keep you apprised of further Medicare compliance developments as they become available.

 

CMS and Medicaid to Convert to CDC 2015 Life Table

The Centers for Medicare and Medicaid Services has announced that it will convert to the CDC’s “Table 1: Life Table for the total population: United States, 2015“ for Workers’ Compensation Medicare Set-Aside life expectancy calculations.  The change to the updated life table will become effective as of January 5, 2019.  There is a slight increase in life expectancy reflected in the new table and in some circumstances this may decrease WCMSA calculations.  All WCMSAs should reflect the updated life table changes from January 5, 2019 and ongoing.

For further information regarding this alert or any Medicare compliance needs, please contact the NuQuest Legal Team.

The OMB Issues Intent of Notice of Proposed Rule Making for Section 111 Penalties

In an abstract entitled “Civil Money Penalties and Medicare Secondary Payer Reporting Requirements,” the Office of Management and Budget has issued another intent of Notice of Proposed Rulemaking this time involving Section 111 Reporting penalties.  Specifically, the abstract of the Notice provides as follows:

Section 516 of the Medicare Access and CHIP Reauthorization Act of 2015 amended the Social Security Act (the Act) by repealing certain duplicative Medicare Secondary Payer reporting requirements. This rule would propose to remove obsolete Civil Money Penalty (CMP) regulations associated with this repeal. The rule would also propose to replace those obsolete regulations by soliciting public comment on proposed criteria and practices for which CMPs would and would not be imposed under the Act, as amended by Section 203 of the Strengthening Medicare and Repaying Taxpayers Act of 2012 (SMART Act).

Pursuant to the SMART Act, civil penalties for non-compliance with Section 111 are up to $1,000 per day, per claimant.  However, no official guidance regarding how these penalties will be determined and enforced has been issued by CMS.  Similar to the Notice issued by the OMB we reported on last week involving Liability Medicare Set-Asides, action to be taken on the Notice of Proposed Rulemaking is set to take place in September 2019.  NuQuest will continue to keep you abreast of any additional developments as they become available.  For  further questions regarding this Notice or for any of your Medicare compliance needs, please contact the NuQuest Legal Team.

Office of Management and Budget Issues Proposed Rulemaking Regarding MSP Compliance Options

Under the title “ Miscellaneous Medicare Secondary Payer Clarifications and Updates,” the Office of Management and Budget issued proposed rulemaking to address Medicare Secondary Payer obligations in the context of automobile and liability insurance, no-fault insurance and workers’ compensation recovery.  The abstract of the proposed rule states as follows:

“This proposed rule would ensure that beneficiaries are making the best health care choices possible by providing them and their representatives with the opportunity to select an option for meeting future medical obligations that fits their individual circumstances, while also protecting the Medicare Trust Fund. Currently, Medicare does not provide its beneficiaries with guidance to help them make choices regarding their future medical care expenses when they receive automobile and liability insurance (including self-insurance), no fault insurance, and workers’ compensation settlements, judgments, awards, or payments, and need to satisfy their Medicare Secondary Payer (MSP) obligations.”

Although there is no legal deadline listed as part of the posting, the timetable for the Notice of Proposed Rule Making is September 2019.   NuQuest will continue to monitor the proposed rulemaking process and will provide updates as they become available.  Should you have any questions regarding the above or need any Medicare compliance assistance, please contact the NuQuest Legal Team.

For more information, go to: https://bit.ly/2QCe6d